Merck Kgaa (MKGAF)

$157.08 8.25 (4.99%)

13:15 EDT MKGAF Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 82

Day's Range $157.08 - $166.52

52-Week Range $143.46 - $186.41

Dividend & Yield N/A (N/A)

MKGAF Stock Predictions, Articles, and Merck Kgaa News

From the Web

Exscientia stock rises as Merck KGaA joins AI drug discovery (NASDAQ:EXAI)

From Seeking Alpha Sep 20, 2023

Exscientia plc (EXAI) added ~20% pre-market Wednesday after Merck KGaA (MKGAF) announced a collaboration with the company for AI drug discovery. Read more here.

HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna (RHHBY)

From Seeking Alpha Jul 17, 2023

HSBC initiated coverage of 19 major biopharma stocks this past week, labeling Roche, Merck KGaA and Lonza as buys, and Bristol-Myers, GSK and Moderna as reduce. Read more here.

Maravai LifeSciences stock gains on report of takeover interest from Germany's Merck

From Seeking Alpha Jul 14, 2023

Maravai LifeSciences (MRVI) rose 3.4% amid a report that Germany's Merck KGaA (MKGAF) is speculated to be one of the companies looking at the vaccine reagent vendor.Merck (MKGAF) is...

Oncolytics stock falls on data for breast cancer therapy

From Seeking Alpha May 26, 2023

Oncolytics Biotech (ONCY) shed ~16% Friday after announcing Phase 2 data for its experimental breast cancer therapy pelareorep in a combination regimen. Read more here.

Merck KGaA stock falls after FDA pauses new patients on MS drug evobrutinib

From Seeking Alpha Apr 12, 2023

Merck KGaA (MKGAF) (MKKGY) said the U.S. FDA placed a partial clinical hold on starting new patients on MS drug evobrutinib. Read more here

Seagen/Pfizer deal spread becoming increasingly attractive, analyst says

From Seeking Alpha Apr 2, 2023

The deal spread in Pfizers (PFE) planned $43 billion purchase of Pfizer (PFE) is attractive with investors seeing decent upside upside from current levels, according to an...

ADVERTISEMENT